Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2 4Phase 1/2 3Phase 1 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Carcinoma, Renal Cell 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2

Interventions

pembrolizumab 42Specimen Handling 38Magnetic Resonance Spectroscopy 30Carboplatin 30Cyclophosphamide 27Biopsy 25Nivolumab 23Dexamethasone 22fludarabine 21Gemcitabine 19Bevacizumab 15Paclitaxel 14Temozolomide 13Pemetrexed 13Docetaxel 13Cisplatin 13atezolizumab 12Ipilimumab 12Rituximab 11venetoclax 10Prednisone 10Lenalidomide 9Injections 9Fulvestrant 9lenvatinib 8X-Rays 8Vincristine 8Trastuzumab 8Oxaliplatin 8Fluorouracil 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × belzutifan × 30 days × Clear all
NCT07049926 2026-05-26

MK-3475-03C

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
140 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT04626479 2026-05-18

MK-3475-03A

Merck Sharp & Dohme LLC

Phase 1/2 Active not recruiting
400 enrolled
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04626518 2026-05-06

KEYMAKER-U03

Merck Sharp & Dohme LLC

Phase 1/2 Active not recruiting
370 enrolled
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡